Berberine Loaded Phospholipid Solid Dispersion for the Treatment of Type 2 Diabetes Mellitus by Ameliorating Oxidative Stress
TONG Shuai1, YIN Ming-xing1, MA Yong-gui1*, SHI Chun-yang1, FANG Jian-guo1,2*
1. Department of Pharmacy, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; 2. Tongji-Rongcheng Center for Biomedicine, Huazhong University of Science and Technology, Wuhan 430030, China
Abstract：OBJECTIVE To prepare berberine(BBR) loaded phospholipid solid dispersion and realize the enhanced drug absorption and antidiabetic effect.. METHODS Berberine (BBR) loaded phospholipid solid dispersion (SD) was prepared by solvent evaporation method. The particle size, morphology, in vitro release property, gastrointestinal absorption profile, antidiabetic effect and mechanism of SD were fully investigated. RESULTS SD was with a mean hydrodynamic diameter of ≈118 nm and a near spherical shape. SD exhibited faster in vitro BBR release, enhanced in vivo gastrointestinal absorption than free BBR, and thus resulted in significantly decreased fasting blood glucose, insulin, triglycerides, total cholesterol, low density lipoprotein and liver malondialdehyde levels, and significantly increased the liver superoxide dismutase, glutathione levels and expression of HO-1in T2DM mice compared with free BBR, which demonstrated tissue protection of SD. CONCLUSION SD can significantly increase the gastrointestinal absorption and antidiabetic effect of BBR via ameliorating oxidative stress in T2DM mice.
International Diabetes Federation: Global diabetes data report 2010-2045[R]. IDF, 2019.
[2]
Manuscript A, Metabolism D: NIH Public Access[J]. Eur J Clin Pharmacol, 2010, 87:507-520.
[3]
ZHOU J, PAN J, XIANG Z, et al. Xiaokeyinshui extract combination, a berberine-containing agent, exerts anti-diabetic and renal protective effects on rats in multi-target mechanisms[J]. J Ethnopharmacol, 2020, 262(15):113098.
[4]
IMENSHAHIDI M, HOSSEEINZADEH H. Berberine and barberry (Berberis vulgaris): A clinical review[J]. Phytother Res, 2019, 33(3):504-523.
[5]
ZHANG Y, LI X, ZOU D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine[J]. J. Clin Endocrinol Metab, 2008, 93(7):2559-2565.
[6]
IMENSHAHIDI M, HOSSEEINZADEH H. Berberis vulgaris and berberine: An update review[J]. Phytother Res, 2016, 30(11):1745-1764.
[7]
XU X, YI H, WU J, et al. Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence[J]. Biomed Pharmacother, 2021, 133(4):110984.
[8]
TAPEINOS C, BATTAGLINI M, CIOFANI G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases[J]. J Controlled Release, 2017, 264:306-332.
[9]
LIU C S, ZHENG Y R, ZHANG Y F, et al. Research progress on berberine with a special focus on its oral bioavailability[J]. Fitoterapia, 2016, 109(1):274-282.
[10]
LANZA F L, MARATHI U K, ANAND B S, et al. Clinical Trial: comparison of Ibuprofen-PC and ibuprofen on the GI safety and analgesic efficacy in osteoarthritic patients[J]. Aliment Pharmacol Ther, 2008, 28(4):431-442.
[11]
HABTEMARIAM S. The quest to enhance the efficacy of berberine for type-2 diabetes and associated diseases: Physicochemical modification approaches[J]. Biomedicines, 2020, 8(4):1-19.
[12]
SHI C Y, TONG Q, FANG J G, et al. Preparation, characterization and in vivo studies of amorphous solid dispersion of berberine with hydrogenated phosphatidylcholine[J]. Eur J Pharm Sci, 2015, 74(1):11-17.
[13]
MIRHADI E, REZAEE M, MALAEKEH-NIKOUEI B. Nano strategies for berberine delivery, a natural alkaloid of Berberis[J]. Biomed Pharmacother, 2018, 104(1):465-473.
[14]
ZHANG Z, CHEN Y, DENG J, et al. Solid dispersion of berberine-phospholipid complex/TPGS 1000/SiO2: preparation, characterization and in vivo studies[J]. Int J Pharm, 2014, 465(1-2):306-316.
[15]
LI C, XU S, LIU Z, DING L, et al. Evaluation of a non-aqueous ibuprofen-phospholipid complex formulation in rats[J]. In Vivo, 2016, 30(4):479-483.
[16]
WANG L, LI H, WANG S, et al. Enhancing the antitumor activity of berberine hydrochloride by solid lipid nanoparticle encapsulation[J]. AAPS Pharm Sci Tech. 2014,15(4):834-844.
[17]
YU F, LI Y, CHEN Q, et al. Monodisperse microparticles loaded with the self-assembled berberine-phospholipid complex-based phytosomes for improving oral bioavailability and enhancing hypoglycemic efficiency[J]. Eur J Pharm Biopharm, 2016, 103(1):136-148.
[18]
XUE M, ZHANG L, YANG MX, et al. Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice[J]. Int J Nanomed, 2015, 10(1):5049-5057.
[19]
XUE M,YANG M X,ZHANG W, et al. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles[J]. Int J Nanomed, 2013, 8(1):4677-4687.
[20]
MOGHADDAM HK, BALUCHNEJADMOJARAD T, ROGHANI M, et al. Berberine ameliorate oxidative stress and astrogliosis in the hippocampus of STZ-induced diabetic rats[J]. Mol Neurobiol, 2013, 49(2):820-826.
[21]
MA X, CHEN Z, WANG L, et al. The pathogenesis of diabetes mellitus by oxidative stress and inflammation: Its inhibition by berberine[J]. Front Pharmacol, 2018, 9(1):782.
[22]
LEE D, BAE J, KIM Y K, et al. Inhibitory effects of berberine on lipopolysaccharide-induced inducible nitric oxide synthase and the high-mobility group box 1 release in macrophages[J]. Biochem Biophys Res Commun, 2013, 431(3):506-511.
[23]
TANG LQ, WEI W, CHEN LM, et al. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats[J]. J Ethnopharmacol, 2006, 108(1):109-115.
2022, Vol. 57 
